CompletedNot Applicable

Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab

South Korea10,067 participantsStarted 2022-07-06

Plain-language summary

This observational study is a large-scale, prospective, and multi-institutional observational study. Patients from 19 to 75 years of age, will take a self-assessment (PRO) during the study period before and after administration of Pexuclue tablet.

Who can participate

Age range19 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adult aged 19 years to 75 years (on registration date)
✓. Patient scheduled to administer Fexuclue tablet based on the medical judgment of investigator.
✓. Patient who agreed to participate in this observation study and signed Informed Consent Form

Exclusion criteria

✕. A person who falls under the prohibition of administration according to the permission for Fexuclue Tablet
✕. A person who participates in another clinical trial and is administering (applying) clinical trial drugs or clinical trial medical devices;
✕. In addition to the above, a person who has determined that the researcher (the doctor in charge) is not suitable for participation in this observation study

What they're measuring

Average score change in RDQ

Timeframe: At least 2 weeks (up to 8 weeks)

Trial details

NCT IDNCT05614752

SponsorDaewoong Pharmaceutical Co. LTD.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2023-12-31

View on ClinicalTrials.gov More Gastroesophageal Reflux Disease trials